Theseus Pharmaceuticals Inc (THRX)

NASDAQ
7.35
-0.67(-8.35%)
  • Volume:
    24,713
  • Day's Range:
    7.35 - 8.10
  • 52 wk Range:
    7.00 - 24.54

THRX Overview

Prev. Close
8.02
Day's Range
7.35-8.1
Revenue
-
Open
7.89
52 wk Range
7-24.54
EPS
-
Volume
24,713
Market Cap
278.99M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
45,011
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
37,958,035
Next Earnings Date
Aug 31, 2022
What is your sentiment on Theseus Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Theseus Pharmaceuticals Inc News

Theseus Pharmaceuticals Inc Company Profile

Theseus Pharmaceuticals Inc Company Profile

Employees
26

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell